Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Lab Anim ; 48(4): 292-7, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25097255

ABSTRACT

The use of germ-free (GF) isolators for microbiome-related research is exponentially increasing, yet limited by its cost, isolator size and potential for trans-contamination. As such, current isolator technology is highly limiting to researchers engaged in short period experiments involving multiple mouse strains and employing a variety of mono-inoculated microorganisms. In this study, we evaluate the use of positive pressure Isocages as a solution for short period studies (days to 2-3 weeks) of experimentation with GF mice at multiple simultaneous conditions. We demonstrate that this new Isocage technology is cost-effective and room-sparing, and enables maintenance of multiple simultaneous groups of GF mice. Using this technology, transferring GF mice from isolators to Isocage racks for experimentation, where they are kept under fully germ-free conditions, enables parallel inoculation with different bacterial strains and simultaneous experimentation with multiple research conditions. Altogether, the new GF Isocage technology enables the expansion of GF capabilities in a safe and cost-effective manner that can facilitate the growth, elaboration and flexibility of microbiome research.


Subject(s)
Animal Husbandry/methods , Animal Husbandry/economics , Animals , Female , Germ-Free Life , Male , Mice , Time Factors
2.
Acta Diabetol ; 43(2): 46-51, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16865329

ABSTRACT

Drugs modulating the ATP-sensitive potassium (K(ATP)) channel activity are widely used for the treatment of diabetes mellitus, the target being pancreatic beta-cells. However, any cell type possessing K(ATP) channels might be concomitantly affected. We investigated the metabolic effect of glibenclamide, a K(ATP) channel closer, and/or diazoxide, a K(ATP) channel opener, on total intracellular content of calcium (Ca) and magnesium (Mg) of cultured peripheral blood mononuclear cells (PBMC). Metformin and rosiglitazone, acting via cellular mechanisms other than K(ATP) channels, were also tested. Ca and Mg were assessed in PBMC from healthy subjects following 72 h in vitro treatment with the respective drugs. Ca content increased significantly in PBMC treated with glibenclamide or rosiglitazone, however apparently via different intracellular pathways. Mg increased only following treatment with rosiglitazone. Metformin had no effect on intracellular Ca or Mg. Pretreatment with diazoxide resulted in a significant intracellular Ca and Mg loss in each experimental situation. If verified clinically, rosiglitazone-induced increase in Mg content of PBMC might prove beneficial beyond hypoglycaemic control. On the other hand, loss of intracellular Ca/Mg content following K(ATP) channel opening by diazoxide might eventually result in significant intracellular Ca and/or Mg depletion.


Subject(s)
Calcium/blood , Hypoglycemic Agents/pharmacology , Leukocytes/drug effects , Magnesium/blood , Adult , Cells, Cultured , Diazoxide/pharmacology , Glyburide/pharmacology , Humans , Metformin/pharmacology , Middle Aged , Potassium Channels/metabolism , Rosiglitazone , Thiazolidinediones/pharmacology
3.
Infection ; 32(3): 179-81, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15188080

ABSTRACT

We describe two splenectomized patients admitted with pneumonia. The course in one was complicated by overwhelming multiorgan failure when the only indicative laboratory result was seropositivity for Legionella hackeliae and Legionella longbeachae. He was initially treated with ceftriaxone and roxithromycin, followed by levofloxacin as well as intensive supportive treatment, and survived. The second patient was seroreactive for Legionella micdadei. In some cases of pneumonia in splenectomized patients tentatively considered to be caused by Streptococcus pneumoniae, the causative agent might have, in fact, been Legionella. We suggest that splenectomy be considered a possible predisposing factor for Legionella pneumonia. Since prompt diagnosis of Legionella infection, especially the non- pneumophila species, is extremely difficult, alertness to this diagnostic option and early empirical initiation of appropriate aggressive antibiotic treatment may be of critical importance.


Subject(s)
Antibodies, Bacterial/blood , Legionella longbeachae/immunology , Legionella/immunology , Legionnaires' Disease/epidemiology , Legionnaires' Disease/microbiology , Splenectomy/adverse effects , Adult , Causality , Community-Acquired Infections/epidemiology , Community-Acquired Infections/microbiology , Female , Humans , Male
4.
Clin Nephrol ; 61(3): 177-84, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15077868

ABSTRACT

AIMS: Many congestive heart failure (CHF) patients suffer from various comorbidities, which may aggravate CHF or independently increase mortality risk. Renal failure (RF) is one of them. We defined bedside clinical, laboratory and electrocardiographic parameters characterizing CHF patients with and without concomitant RF, and analyzed their impact on mortality. METHODS: We studied symptomatic unselected consecutive furosemide-treated CHF patients hospitalized for various acute conditions. On admission, history taking, physical examination, chest x-ray, ECG and routine laboratory tests were performed. Subsequently, patients were divided into 2 subgroups, those with serum creatinine > or = 1.5 mg/dl (RF) and those with lower values. Following discharge, information concerning mortality and circumstance of death was obtained from hospital records and outpatient death certificates. RESULTS: Included were 398 patients, 163 (40.9%) with RF and 235 free of RF. Prevailing in the RF subgroup were older age (mean age 75.5 vs 70.8, p < 0.001), male gender (p < 0.001), admission pulmonary edema (p = 0.007), cardiac arrhythmias (p = 0.05), cardiac conduction disturbances (p = 0.002), severe CHF (p = 0.005), lower ejection fraction (p = 0.03), anemia (p = 0.009), higher furosemide maintenance dosages (p < 0.001), insulin treatment (p = 0.03) and receiving less ACE inhibitors (p = 0.006). On median follow-up of 43 months, mortality was 54.9% in the RF vs 31.9% in the non-RF subgroup (p < 0.001), RF being the parameter most significantly associated with low survival (OR 1.97, p < 0.001). In the RF subgroup older age (p < 0.02), female gender (p < 0.003) and not using ACE inhibitors (p = 0.04) or drugs with antiarrhythmic effects (p < 0.005), emerged significantly associated with low survival, while diabetes mellitus (DM) and admission pulmonary edema tended to be so associated (p < 0.2). Using multivariate analysis in the RF subgroup, older age, female gender and DM proved most significantly associated with poorer survival (p = 0.004, OR 1.5, p = 0.03, OR 1.72, p = 0.04, OR 1.28, respectively). In the non-RF subgroup, only older age (p = 0.005) and DM (p = 0.05) were significantly associated with low survival. Sudden death occurred in 21 patients, 14 (8.6%) in the RF and 7 (3%) in the non-RF subgroup (p < 0.001). CONCLUSIONS: RF is a marker of severity in CHF. Its full-blown deleterious prognostic effect is already manifested at serum creatinine 1.5 mg/dl. Older age, DM and female gender most significantly heralded a shorter survival. Such patients require special care.


Subject(s)
Heart Failure/physiopathology , Renal Insufficiency/physiopathology , Aged , Case-Control Studies , Comorbidity , Diabetes Mellitus/epidemiology , Female , Heart Failure/complications , Heart Failure/mortality , Humans , Male , Multivariate Analysis , Prognosis , Proportional Hazards Models , Prospective Studies , Renal Insufficiency/complications , Renal Insufficiency/mortality , Risk Factors , Sex Factors , Survival Analysis
5.
Heart ; 89(4): 411-6, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12639869

ABSTRACT

OBJECTIVES: To determine the prevalence of hypomagnesaemia and hypermagnesaemia, to discern various factors associated with abnormal serum magnesium, and to estimate prognostic significance of serum magnesium aberrations in patients with congestive heart failure. DESIGN: Observational study. SETTING: Medical department of a university hospital (tertiary referral centre). PATIENTS: 404 consecutive patients admitted with congestive heart failure as one of the diagnoses and previously treated with furosemide (frusemide) for at least three months. MAIN OUTCOME MEASURES: Clinical, biochemical, and electrocardiographic variables were analysed with respect to serum magnesium aberrations. Following discharge, mortality rates, including sudden death, were registered. RESULTS: Hypomagnesaemia was found in 50 patients (12.3%) and 20 (4.9%) were hypermagnesaemic. Female sex (p < 0.04), diabetes mellitus (p < 0.006), hypocalcaemia (p = 0.03), hyponatraemia (p < 0.05), malignant disease (p = 0.05), and high fever (p = 0.05) were statistically associated with hypomagnesaemia. Renal failure, severe congestive heart failure, and high dose furosemide treatment (> 80 mg/day) were associated with hypermagnesaemia (p < 0.001, p = 0.05, and p < 0.03, respectively). Hypermagnesaemic patients were older and weighed less. On follow up (median duration 43 months), 169 (41.8%) died, with 22 (13%) sudden deaths. Mortality was highest with hypermagnesaemia, lowest with normomagnesaemia, and intermediate with hypomagnesaemia. After adjustment for renal failure, old age, and severity of congestive heart failure, hypomagnesaemia but not hypermagnesaemia emerged as being significantly associated with shorter survival (p = 0.009). No statistical association was found between sudden death and magnesium concentrations. CONCLUSIONS: While hypermagnesaemia seems to represent a prognostic marker only, hypomagnesaemia appears to have an adverse pathophysiological effect. The subgroup of patients at risk for hypomagnesaemia requires frequent serum magnesium determinations and magnesium replacement for as long as hypomagnesaemia persists.


Subject(s)
Diuretics/therapeutic use , Furosemide/therapeutic use , Heart Failure/drug therapy , Magnesium Deficiency/complications , Magnesium/blood , Aged , Female , Heart Failure/blood , Heart Failure/mortality , Humans , Magnesium Deficiency/blood , Male , Prognosis , Risk Factors , Survival Analysis
6.
Rheumatol Int ; 20(4): 163-6, 2001 May.
Article in English | MEDLINE | ID: mdl-11411962

ABSTRACT

Acute inflammatory myopathy with severe subcutaneous edema is extremely rare and has been reported in only a handful of cases. We describe two similar patients presenting with this disorder and generalized rash. Unlike the five previously reported cases, the clinical and histologic features of our two patients are more suggestive of dermatomyositis than polymyositis. Nevertheless, scrutinizing all seven reported patients, a number of specific characteristics could be defined. All patients were adult males. Dysphagia was present in four. In six patients, acute inflammatory myopathy was idiopathic while malignancy was present in one. Two patients died despite intensive therapy, three improved on corticosteroid treatment, and two recovered spontaneously. In all patients, limb involvement with marked subcutaneous edema was present, clinically mimicking deep vein thrombosis in both our patients. The presence of severe subcutaneous edema may be a hallmark of a distinctive variant of acute inflammatory myopathy. More cases are needed to discern subtypes of this general entity and to establish guidelines for treatment and prognosis.


Subject(s)
Edema/complications , Myositis/complications , Skin Diseases/complications , Acute Disease , Adrenal Cortex Hormones/therapeutic use , Adult , Edema/diagnosis , Follow-Up Studies , Humans , Male , Middle Aged , Myositis/diagnosis , Myositis/drug therapy , Severity of Illness Index , Skin Diseases/diagnosis , Treatment Outcome
7.
Clin Cardiol ; 24(5): 380-4, 2001 May.
Article in English | MEDLINE | ID: mdl-11346246

ABSTRACT

BACKGROUND: Despite reported evidence of the vital importance of appropriate anticoagulation in patients with chronic atrial fibrillation for stroke prevention, this treatment modality still lags behind optimal requirements. HYPOTHESIS: Our objectives were to evaluate various doctor or patient-related factors that influence quality of control and to assess the adequacy of anticoagulation provided by physicians in the community. METHODS: In a retrospective study, International Normalized Ratio (INR) values obtained immediately on admission to hospital were considered representative of previous long-term control. RESULTS: Only 42% of the relevant 385 patient population fell within the protective anticoagulation range of INR 1.91-4.1. The respective figures for patients with poor (INR < 1.5) or suboptimal (INR 1.51-1.9) control, as well as those whose INR values risked bleeding (INR > 4.1), were 28.3, 14.1, and 15.6%. Patient involvement in treatment positively influenced quality of control. By contrast, age 70-80 years or absence of congestive heart failure negatively affected quality of anticoagulation [p = 0.07, odds ratio (OR), 1.7 (95% confidence interval. 0.94-3.08), p = 0.014, OR, 2.06 (95% confidence interval, 1.15-3.7) respectively]. The percentage of patients admitted with stroke who had been adequately anticoagulated was significantly lower than that of patients who had no stroke (21 vs. 44.4%). Adequacy of anticoagulation in patients with cardiac prosthetic valves was superior compared with the rest of the patient population (56.7 vs. 42% with optimal, and only 14.5 vs. 28.3% with poor anticoagulation, respectively), indicating that under the same conditions a better quality of treatment could be achieved. CONCLUSIONS: Adequacy of anticoagulation in patients with atrial fibrillation lags behind actual recommendations. Better control is required and achievable.


Subject(s)
Atrial Fibrillation/complications , International Normalized Ratio , Stroke/prevention & control , Aged , Aged, 80 and over , Female , Guideline Adherence , Heart Valve Prosthesis , Humans , Male , Multivariate Analysis , Quality of Health Care , Retrospective Studies , Stroke/complications , Treatment Outcome
8.
J Infect ; 41(3): 277-82, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11120621

ABSTRACT

We describe two patients with acute leukaemia who died of massive haemoptysis caused by invasive pulmonary aspergillosis (IPA). The fatal event occurred during the period of bone marrow remission which followed chemotherapy-induced neutropenia. This is a rare complication. We were able to find additional 17 similar cases in the English literature, which we review. Clinically, the picture consisted of unremitting fever with profound and prolonged neutropenia, cough and dyspnoea. Both our patients were treated with broad-spectrum antibiotics, fluconazole and amphotericin B. An upper lobe infiltrate in one case, and a progressive pleural effusion in the other, were late findings on chest radiographs during the period of bone marrow recovery. Both patients succumbed to sudden massive haemoptysis during the period of bone marrow and clinical improvement. In conclusion, patients with acute non-lymphoid leukaemia are at significant risk for IPA-induced fatal haemoptysis during bone marrow and clinical remission. A high index of suspicion should be sustained throughout the entire clinical course. In view of the potential fatal outcome, aggressive diagnostic and treatment efforts are mandatory.


Subject(s)
Aspergillosis/complications , Hemoptysis/etiology , Leukemia, Myeloid/drug therapy , Lung Diseases, Fungal/complications , Acute Disease , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fatal Outcome , Female , Humans , Leukemia, Myeloid/complications , Middle Aged , Remission Induction
9.
Stroke ; 31(6): 1217-22, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10835435

ABSTRACT

BACKGROUND AND PURPOSE: The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established. However, the prevalence of such treatment generally lags behind actual requirements. The aim of this study was to evaluate doctor- and/or patient-related demographic, clinical, and echocardiographic factors that influence decision for warfarin treatment. METHODS: Between 1990 and 1998, 1027 patients were discharged with chronic or persistent atrial fibrillation. This population was composed of (1) patients with cardiac prosthetic valves (n=48), (2) those with increased bleeding risks (n=152), (3) physically or mentally handicapped patients (n=317), and (4) the remaining 510 patients, the main study group who were subjected to thorough statistical analysis for determining factors influencing warfarin use. RESULTS: The respective rates of warfarin use on discharge in the 4 groups were 93.7%, 30.9%, 17.03%, and 59.4% (P=0.001); of the latter, an additional 28.7% were discharged on aspirin. In the main study group, warfarin treatment rates increased with each consecutive triennial period (29.7%, 53.6%, and 77.1%, respectively; P=0.001). Age >80 years, poor command of Hebrew, and being hospitalized in a given medical department emerged as independent variables negatively influencing warfarin use: P=0.0001, OR 0.30 (95% CI 0.17 to 0.55); P=0.02, OR 0.59 (95% CI 0.36 to 0.94); and P=0.0002, OR 0.26 (95% CI 0.12 to 0.52), respectively. In contrast, past history of stroke and availability of echocardiographic information, regardless of the findings, each increased warfarin use (P=0.03, OR 1.95 [95% CI 1.04 to 3.68], and P=0.0001, OR 3.52 [95% CI 2.16 to 5.72], respectively). CONCLUSIONS: Old age, language difficulties, insufficient doctor alertness to warfarin benefit, and patient disability produced reluctance to treat. Warfarin use still lags behind requirements.


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Practice Patterns, Physicians' , Stroke/prevention & control , Warfarin/therapeutic use , Age Factors , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Aspirin/administration & dosage , Aspirin/therapeutic use , Atrial Fibrillation/complications , Atrial Fibrillation/diagnostic imaging , Atrial Fibrillation/epidemiology , Chronic Disease , Communication Barriers , Comorbidity , Drug Prescriptions/statistics & numerical data , Drug Utilization , Echocardiography , Female , Heart Diseases/complications , Heart Diseases/diagnostic imaging , Heart Diseases/epidemiology , Hospital Departments , Hospitalization , Humans , Israel , Lung Diseases, Obstructive/epidemiology , Male , Middle Aged , Physician-Patient Relations , Physicians/psychology , Recurrence , Refusal to Treat , Retrospective Studies , Risk Factors , Stroke/etiology , Thyrotoxicosis/epidemiology , Warfarin/administration & dosage
10.
Clin Cardiol ; 23(6): 433-6, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10875034

ABSTRACT

BACKGROUND: Magnesium depletion and hypomagnesemia are common among furosemide-treated patients with chronic congestive heart failure. HYPOTHESIS: This investigation evaluated clinical and metabolic effects of oral magnesium supplementation. METHODS: Ten patients with severe congestive heart failure maintained on high dose furosemide (> or = 80 mg/day) received a supplement of oral magnesium citrate 300 mg/daily for 30 days. Clinical parameters were followed, and peripheral blood mononuclear cell magnesium and zinc content, serum and urine magnesium, potassium, zinc, calcium, phosphorus, and creatinine were assessed. RESULTS: Peripheral blood mononuclear cell magnesium content and serum potassium rose significantly at the end of the study (2.09 +/- 1.89 to 3.99 +/- 2.26 micrograms/mg cell protein, p < 0.05, and 4.17 +/- 0.38 to 4.39 +/- 0.27 mEq/l, p < 0.05, respectively), while the other parameters remained unchanged. CONCLUSION: In some of these patients, oral magnesium supplementation is effective in achieving substantial increments in intracellular magnesium and serum potassium which, in turn, may have cardioprotective effects.


Subject(s)
Citric Acid/pharmacology , Dietary Supplements , Diuretics/therapeutic use , Furosemide/therapeutic use , Heart Failure/drug therapy , Organometallic Compounds/pharmacology , Administration, Oral , Adult , Aged , Cardiomyopathy, Dilated/complications , Citric Acid/administration & dosage , Female , Heart Failure/etiology , Heart Failure/metabolism , Humans , Male , Middle Aged , Myocardial Ischemia/complications , Organometallic Compounds/administration & dosage
11.
J Clin Gastroenterol ; 29(1): 59-62, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10405234

ABSTRACT

Metoclopramide, a benzamide substitute, is used frequently as an antiemetic drug. Sulpiride, another benzamide substitute, was investigated and found to be safe and effective in a handful of studies involving only oncologic or other severely symptomatic patients. In this investigation the authors compared prospectively the antiemetic efficacy of sulpiride versus metoclopramide in a double-blind, randomized study involving 36 nononcologic patients with transient vomiting or nausea of various etiologies. Each group of 18 patients received oral metoclopramide or sulpiride (10 mg or 50 mg respectively) every 8 hours for a total of three doses each (24 hours of treatment). A 5-point score was used to evaluate symptomatic relief. Efficacy of the two drugs proved similar, and at the end of the study, 14 and 13 of 18 patients on sulpiride or metoclopramide respectively were asymptomatic. Only transient, minor side effects were reported in one patient in each group. The authors conclude that sulpiride is an effective and safe antiemetic drug that can be adopted legitimately in such cases as a first choice, or serve as an equipotent alternative to metoclopramide in patients sensitive to the latter.


Subject(s)
Antiemetics/therapeutic use , Metoclopramide/therapeutic use , Nausea/drug therapy , Sulpiride/therapeutic use , Vomiting/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antiemetics/administration & dosage , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Metoclopramide/administration & dosage , Middle Aged , Prospective Studies , Sulpiride/administration & dosage , Treatment Outcome
12.
Clin Genet ; 52(1): 47-50, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9272712

ABSTRACT

Familial thrombocytosis is an extremely rare disorder, so far reported in only a handful of families. In the majority of cases the characteristics were of essential thrombocythemia. Most patients presented with a platelet count above 800,000/mm3, were diagnosed as having a myeloproliferative disease, and some required chemotherapy. We describe a benign form of familial thrombocytosis with autosomal dominant inheritance in five healthy members of three generations of a family, all of whom had moderate thrombocytosis within the range 422,000-662,000/mm3, characterized by low mean platelet volume. A careful medical history and a 5-year follow up of the subjects did not reveal any untoward clinical development. This variant of familial thrombocytosis is therefore of a benign nature. Possible mechanisms linking thrombocytosis with platelet microcytosis in this family are discussed.


Subject(s)
Blood Platelets/pathology , Thrombocytosis/blood , Thrombocytosis/genetics , Adolescent , Adult , Child , Female , Genes, Dominant/genetics , Humans , India , Jews , Male , Pedigree
13.
Clin Cardiol ; 20(3): 291-4, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9068918

ABSTRACT

Endocarditis is the most devastating complication of brucellosis. The accepted treatment for Brucella endocarditis (BE) is a combination of valve replacement and antibiotics. Conservative antibiotic treatment alone is not recommended by most authors, as it is considered ineffective, risking fatality. We describe a patient with BE, in whom antibiotic treatment alone resulted in complete recovery. On reviewing the literature, we found 12 additional such cases. We compared this group of 13 patients with data from 49 published cases treated with a combination of surgery and antibiotics, with a favorable outcome. Absence of congestive heart failure or a prosthetic valve, relatively mild extravalvular cardiac involvement, and a somewhat shorter disease history until initiation of treatment were characteristic of the group treated conservatively in comparison with patients who underwent surgery. In selected patients with BE, conservative antibiotic treatment may be a valid alternative to surgery.


Subject(s)
Anti-Bacterial Agents , Brucellosis/drug therapy , Drug Therapy, Combination/therapeutic use , Endocarditis, Bacterial/drug therapy , Humans , Male , Middle Aged
14.
Clin Cardiol ; 19(11): 910-2, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8914788

ABSTRACT

Reports of chylothorax (CT) following median sternotomy are rare, amounting so far to 16 cases in the English literature, of which 6 were cases of postcoronary artery bypass grafting (CABG). This report deals with an additional case of a 70-year-old woman who developed left pleural chylous effusion following CABG. It is suggested that the incidence of this type of pleural effusion is considerably greater than the few cases hitherto reported. Moreover, as CT may produce serious pulmonary and/or pleural functional impairment, it is proposed that a diagnostic tap be performed more often in cases of post CABG pleural effusion and that preventive drainage be instituted when CT is diagnosed.


Subject(s)
Chylothorax/etiology , Coronary Artery Bypass/adverse effects , Sternum/surgery , Aged , Female , Humans , Postoperative Complications
15.
Crit Care Med ; 17(3): 279-82, 1989 Mar.
Article in English | MEDLINE | ID: mdl-2920565

ABSTRACT

A model utilizing human umbilical cord blood was used to screen for hypoglycemia in a simulated neonatal situation. The aims of the study were to assess the effect of increasing Hct concentration on Dextrostix readings, and to determine whether plasma samples, in contrast to conventional whole blood samples, were acceptable for Dextrostix determinations in selected cases. Dextrostix readings were determined on 65 whole blood samples of varying Hct, and on plasma specimens, 48 of which were paired with whole blood samples. The results were compared with plasma true glucose values. Plasma Dextrostix readings correlated well with true glucose values throughout the entire Hct range (r = .94, slope = 1.16). Whole blood Dextrostix readings, on the other hand, were Hct-dependent and, with increasing Hct values, became falsely low. As a result, a Hct values greater than 70%, whole blood Dextrostix readings were less than 50% of the true glucose value (r = .94, slope = 0.45). Plasma Dextrostix determinations may offer an accurate means of screening for neonatal hypoglycemia in asymptomatic infants with high Hct, pending laboratory glucose results.


Subject(s)
Blood Glucose/analysis , Chromogenic Compounds , Glucose Oxidase , Hematocrit , Hypoglycemia/blood , Peroxidases , Reagent Strips , Fetal Blood/analysis , Humans , Infant, Newborn , Plasma/analysis , Predictive Value of Tests
16.
Immunol Invest ; 18(1-4): 431-47, 1989.
Article in English | MEDLINE | ID: mdl-2471691

ABSTRACT

We describe here a series of experiments which have been undertaken in the course of several years to try and study secretory mechanisms operative in the release of antibodies in the lumen of the intestine. The results of our experiments suggest that there are a number of stimuli that are efficacious in eliciting antibody release in the lumen of the rat intestine. These include the peptide hormones cholecystokinin and substance P, and cholinergic agonists such as pilocarpine. The fact that food has a similar effect indicates that the stimulation of antibody release is a physiological process co-ordinated with the ingestion of foreign antigens. We have also shown that food mediates its effect by means of cholecystokinin. Cholecystokinin promotes the release of antibodies belonging to the IgA, IgG, IgM and IgE isotypes. There is reason to believe that not all the IgA is secretory IgA. Antibody release can be inhibited by the CCK antagonist proglumide and by cholinergic antagonists. The intracellular messengers that participate in this process are changes in cytosolic calcium. It is proposed that the release of antibodies in the gastrointestinal tract is an active secretory process.


Subject(s)
Antibody Formation , Intestines/immunology , Animals , Antibody Formation/drug effects , Biological Transport, Active/drug effects , Food , Humans , Immunization , Immunoglobulin A, Secretory/biosynthesis , Intestines/drug effects , Ovalbumin/immunology , Pilocarpine/pharmacology , Rats , Sincalide/pharmacology , Substance P/pharmacology
17.
Gastroenterology ; 92(3): 786-90, 1987 Mar.
Article in English | MEDLINE | ID: mdl-3028897

ABSTRACT

Chronic neuropathic intestinal pseudoobstruction is a rare entity, characterized by recurrent episodes of bowel obstruction without a mechanical obstructive cause. We report five members of two Jewish-Iranian families in whom chronic neuropathic intestinal pseudoobstruction was associated with an identical and unique progressive severe neuronal disease. It appeared within the first two decades of life. The disease consisted of external ophthalmoplegia, ptosis, and severe sensory and motor peripheral neuropathy. Three patients also had neuronal hearing loss. There was no evidence of central nervous system involvement and all patients were mentally intact. The combined disease was confirmed by radiologic, electrophysiologic, and histologic studies. Specific nutritional deficiencies, toxic elements, and systemic diseases affecting both the gastrointestinal tract and the nervous system were ruled out. It seems that these patients suffer from an autosomal recessive, presently unrecognized variant, of chronic neuropathic intestinal pseudoobstruction. In a patient with severe peripheral neuropathy of unknown etiology associated with symptoms suggestive of intestinal obstruction, the possibility of chronic neuropathic intestinal pseudoobstruction has to be considered.


Subject(s)
Intestinal Pseudo-Obstruction/genetics , Peripheral Nervous System Diseases/genetics , Adolescent , Adult , Chronic Disease , Hearing Loss, Sensorineural/genetics , Humans , Male , Neuromuscular Diseases/genetics , Ophthalmoplegia/genetics
18.
J Trop Med Hyg ; 89(3): 107-12, 1986 Jun.
Article in English | MEDLINE | ID: mdl-3464761

ABSTRACT

Within a 2 month period 131 Ethiopian immigrants were admitted for treatment at a general hospital in Jerusalem. There were 52 patients with malaria, 13 with typhoid fever, 24 with pneumonia, seven with tuberculosis, nine with shigella and 11 with campylobacter. Over three-quarters of these patients were anaemic. In the majority of cases anaemia was normocytic and was most probably secondary to malaria and other intercurrent infections. The prevalence of diffuse non-toxic goitre was 7% in children and 19% in adults with a male to female ratio of 4:13. A positive rapid plasma reagin (RPR) test was found in 4% of sera tested and a positive HBsAg in 13%. IgG antibodies to HBc antigen were found in 75% of subjects. All patients with infectious diseases responded to therapy and, despite their poor condition at arrival, there were no fatalities and no late sequelae. The high HBsAg carrier state calls attention to the risk of vertical transmission by infected mothers and underlines the need for active immunization of infants at risk. The high prevalence of untreated tuberculosis and malaria poses a potential public health hazard, but with the current systematic screening of this population leading to identification and effective treatment of affected subjects, chances for the practical eradication of malaria and tuberculosis are excellent. Finally, the large scale transfer of a population from rural Africa to a modern and largely urban society presents a unique opportunity for a prospective study of the impact of environment on the emergence of diseases which plague modern society such as diabetes, atherosclerotic cardiovascular disease, hypertension and cancer.


Subject(s)
Refugees , Adolescent , Adult , Anemia/epidemiology , Child , Child, Preschool , Ethiopia/ethnology , Female , Gastrointestinal Diseases/microbiology , Gastrointestinal Diseases/parasitology , Glycogen Storage Disease Type I/epidemiology , Hepatitis B Surface Antigens/analysis , Humans , Israel , Malaria/epidemiology , Male , Pneumonia/epidemiology , Tuberculosis/epidemiology , Typhoid Fever/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...